Optimal management of uterine leiomyosarcoma

References

• Echt G, Jepson J, Steel J et al. Treatment of uterine sarcomas. Cancer66(1), 35–39 (1990).
   PubMed Web of Science ®Google Scholar
• Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int. J. Cancer119(12), 2922–2930 (2006).
   PubMed Web of Science ®Google Scholar
• Major FJ, Blessing JA, Silverberg SG et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer71(4 Suppl.), 1702–1709 (1993).
   PubMed Web of Science ®Google Scholar
• Giuntoli RL 2nd, Metzinger DS, DiMarco CS et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol. Oncol.89(3), 460–469 (2003).
   PubMed Web of Science ®Google Scholar
• Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer112(4), 820–830 (2008).
   PubMed Web of Science ®Google Scholar
• Zivanovic O, Leitao MM, Iasonos A et al. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems. J. Clin. Oncol.27(12), 2066–2072 (2009).
   PubMed Web of Science ®Google Scholar
• Raut CP, Nucci MR, Wang Q et al. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur. J. Cancer45(16), 2818–2824 (2009).
   Google Scholar
• Hensley ML, Ishill N, Soslow R et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I–IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol. Oncol.112(3), 563–567 (2009).
   PubMed Web of Science ®Google Scholar
• Prat J. FIGO staging for uterine sarcomas. Int. J. Gynaecol. Obstet.104(3), 177–179 (2009).
   PubMed Web of Science ®Google Scholar
• Einstein MH, Barakat RR, Chi DS et al. Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease. Int. J. Gynecol. Cancer18(5), 1065–1070 (2008).
   PubMed Web of Science ®Google Scholar
• Lissoni A, Cormio G, Bonazzi C et al. Fertility-sparing surgery in uterine leiomyosarcoma. Gynecol. Oncol.70(3), 348–350 (1998).
   PubMed Web of Science ®Google Scholar
• Cormio G, Loizzi V, Carriero C, Scardigno D, Putignano G, Selvaggi L. Conservative management of uterine leiomyosarcoma: report of a failure. Eur. J. Gynaecol. Oncol.30(2), 206–207 (2009).
   Google Scholar
• Leitao MM, Sonoda Y, Brennan MF, Barakat RR, Chi DS. Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol. Oncol.91(1), 209–212 (2003).
   PubMed Web of Science ®Google Scholar
• Leitao MM, Soslow RA, Nonaka D et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer101(6), 1455–1462 (2004).
   PubMed Web of Science ®Google Scholar
• Goff BA, Rice LW, Fleischhacker D et al. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol. Oncol.50(1), 105–109 (1993).
   PubMedGoogle Scholar
• Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet. Gynecol.83(3), 414–418 (1994).
   PubMed Web of Science ®Google Scholar
• Leibsohn S, d’Ablaing G, Mishell DR Jr, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am. J. Obstet. Gynecol.162(4), 968–974 (1990).
   PubMed Web of Science ®Google Scholar
• Goldberg J, Burd I, Price FV, Worthington-Kirsch R. Leiomyosarcoma in a premenopausal patient after uterine artery embolization. Am. J. Obstet. Gynecol.191(5), 1733–1735 (2004).
   PubMedGoogle Scholar
• Posy HES, Elkas JC, Yemelyanova AV, Diaz-Montes TP, Bristow RE, Giuntoli RL. Metastatic leiomyosarcoma diagnosed after uterine artery embolization. Eur. J. Gynaecol. Oncol.30(2), 199–202 (2009).
   Google Scholar
• Sorbe B, Johansson B. Prophylactic pelvic irradiation as part of primary therapy in uterine sarcomas. Int. J. Oncol.32(5), 1111–1117 (2008).
   PubMed Web of Science ®Google Scholar
• Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int. J. Radiat. Oncol. Biol. Phys.12(12), 2127–2130 (1986).
   Google Scholar
• Sampath S, Schultheiss TE, Ryu JK, Wong JY. The role of adjuvant radiation in uterine sarcomas. Int. J. Radiat. Oncol. Biol. Phys. (2009) (Epub ahead of print).
   Google Scholar
• Reed NS, Mangioni C, Malmström H et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874). Eur. J. Cancer44(6), 808–818 (2008).
   PubMed Web of Science ®Google Scholar
• Leyvraz S, Zweifel M, Jundt G et al. Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Ann. Oncol.17(4), 646–651 (2006).
   Google Scholar
• Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer113(3), 573–581 (2008).
   PubMed Web of Science ®Google Scholar
• Omura G, Blessing J, Major F et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J. Clin. Oncol.3(9), 1240–1245 (1985).
   PubMed Web of Science ®Google Scholar
• Pautier P, Rey A, Haie-Meder C et al. Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone. Int. J. Gynecol. Cancer14(6), 1112–1117 (2004).
   PubMed Web of Science ®Google Scholar
• Hempling RE, Piver MS, Baker TR. Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective trial. Am. J. Clin. Oncol.18(4), 282–286 (1995).
   PubMed Web of Science ®Google Scholar
• Hensley ML, Anderson S, Soslow R et al. Activity of gemcitabine plus docetaxel in leiomyosarcoma (LMS) and other histologies: report of an expanded Phase II trial. J. Clin. Oncol. (Meeting Abstracts)22(14 Suppl.), (2004) (Abstract 9010).
   Google Scholar
• Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group Phase II study. Gynecol. Oncol.109(3), 323–328 (2008).
   PubMed Web of Science ®Google Scholar
• Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group Phase II trial. Gynecol. Oncol.109(3), 329–334 (2008).
   PubMed Web of Science ®Google Scholar
• Leu KM, Ostruszka LJ, Shewach D et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J. Clin. Oncol.22(9), 1706–1712 (2004).
   PubMed Web of Science ®Google Scholar
• Kanjeekal S, Chambers A, Fung MF, Verma S. Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol. Oncol.97(2), 624–637 (2005).
   PubMed Web of Science ®Google Scholar
• Asbury R, Blessing JA, Smith DM, Carson LF. Aminothiadiazole in the treatment of advanced leiomyosarcoma of the uterine corpus. A Gynecologic Oncology Group study. Am. J. Clin. Oncol.18(5), 397–399 (1995).
   PubMed Web of Science ®Google Scholar
• Asbury R, Blessing JA, Buller R, Malfetano JH, Walker J, Sevin BU. Amonafide in patients with leiomyosarcoma of the uterus: a Phase II Gynecologic Oncology Group study. Am. J. Clin. Oncol.21(2), 145–146 (1998).
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Blessing JA, Beecham J, Homesley H, Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J. Clin. Oncol.9(11), 1962–1966 (1991).
   PubMed Web of Science ®Google Scholar
• Slayton RE, Blessing JA, Look K, Anderson B. A Phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus. A Gynecologic Oncology Group study. Invest. New Drugs9(2), 207–208 (1991).
   PubMed Web of Science ®Google Scholar
• Verweij J, Lee SM, Ruka W et al. Randomized Phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol.18(10), 2081–2086 (2000).
   PubMed Web of Science ®Google Scholar
• Rose PG, Blessing JA, Soper JT, Barter JF. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol.70(2), 267–271 (1998).
   PubMed Web of Science ®Google Scholar
• Muss HB, Bundy BN, Adcock L, Beecham J. Mitoxantrone in the treatment of advanced uterine sarcoma. A Phase II trial of the Gynecologic Oncology Group. Am. J. Clin. Oncol.13(1), 32–34 (1990).
   PubMed Web of Science ®Google Scholar
• Gallup DG, Blessing JA, Andersen W, Morgan MA. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol.89(1), 48–51 (2003).
   Google Scholar
• Sutton G, Blessing JA, Ball H. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol.74(3), 346–349 (1999).
   PubMed Web of Science ®Google Scholar
• McMeekin DS, Sill MW, Darcy KM et al. A Phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gynecol. Oncol.106(3), 596–603 (2007).
   PubMed Web of Science ®Google Scholar
• Smith HO, Blessing JA, Vaccarello L. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a Phase II study of the Gynecologic Oncology Group. Gynecol. Oncol.84(1), 140–144 (2002).
   PubMed Web of Science ®Google Scholar
• Slayton RE, Blessing JA, Angel C, Berman M. Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Cancer Treat. Rep.71(12), 1303–1304 (1987).
   PubMedGoogle Scholar
• Thigpen T, Blessing JA, Yordan E, Valea F, Vaccarello L. Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol.63(1), 120–122 (1996).
   PubMed Web of Science ®Google Scholar
• Fidias P, Demetri G, Harmon D. Navelbine shows activity in previously treated sarcoma patients: Phase II results from MGH/Dana Farber/Partner’s Cancercare study. Proc. Am. Soc. Clin. Oncol. (1998) (Abstract 1977).
   Google Scholar
• Anderson SE, Keohan ML, D’Adamo DR, Maki RG. A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. Sarcoma2006, 15947 (2006).
   Google Scholar
• Miller DS, Blessing JA, Kilgore LC, Mannel R, Van Le L. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group study. Am. J. Clin. Oncol.23(4), 355–357 (2000).
   PubMed Web of Science ®Google Scholar
• Omura GA, Major FJ, Blessing JA et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer52(4), 626–632 (1983).
   PubMed Web of Science ®Google Scholar
• Sutton GP, Blessing JA, Barrett RJ, McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am. J. Obstet. Gynecol.166(2), 556–559 (1992).
   PubMed Web of Science ®Google Scholar
• Look KY, Sandler A, Blessing JA, Lucci JA 3rd, Rose PG. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol. Oncol.92(2), 644–647 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson S, Aghajanian C. Temozolomide in uterine leiomyosarcomas. Gynecol. Oncol.98(1), 99–103 (2005).
   PubMed Web of Science ®Google Scholar
• Talbot SM, Keohan ML, Hesdorffer M et al. A Phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer98(9), 1942–1946 (2003).
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG, Maki RG et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter Phase II and pharmacokinetic study. J. Clin. Oncol.23(24), 5484–5492 (2005).
   PubMed Web of Science ®Google Scholar
• Grosso F, Sanfilippo R, Jones RL et al. Role of trabectedin (T) in the management of advanced uterine leiomyosarcoma (U-LM). J. Clin. Oncol.27(15S), (2009) (Abstract 10530).
   Google Scholar
• Sutton G, Blessing J, Hanjani P, Kramer P. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol.96(3), 749–752 (2005).
   PubMed Web of Science ®Google Scholar
• Lorigan P, Verweij J, Papai Z et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma group study. J. Clin. Oncol.25(21), 3144–3150 (2007).
   PubMed Web of Science ®Google Scholar
• Hensley ML, Hagerty KL, Kewalramani T et al. American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol.27(1), 127–145 (2009).
   PubMed Web of Science ®Google Scholar
• Dileo P, Morgan J, Zahrieh D et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a Phase II trial. Cancer109(9), 1863–1869 (2007).
   PubMed Web of Science ®Google Scholar
• Minuzzo M, Marchini S, Broggini M, Faircloth G, D’Incalci M, Mantovani R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc. Natl Acad. Sci. USA97(12), 6780–6784 (2000).
   PubMed Web of Science ®Google Scholar
• Jin S, Gorfajn B, Faircloth G, Scotto KW. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc. Natl Acad. Sci. USA97(12), 6775–6779 (2000).
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG, Manola J et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J. Clin. Oncol.22(8), 1480–1490 (2004).
   PubMed Web of Science ®Google Scholar
• Yovine A, Riofrio M, Blay JY et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J. Clin. Oncol.22(5), 890–899 (2004).
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol.23(3), 576–584 (2005).
   PubMed Web of Science ®Google Scholar
• Beumer JH, Schellens JHM, Beijnen JH. Hepatotoxicity and metabolism of trabectedin: a literature review. Pharmacol. Res.51(5), 391–398 (2005).
   PubMed Web of Science ®Google Scholar
• Cioffi A, LeCesne A, Blay J et al. Trabectedin Phase II clinical trials: pooled analysis of safety in patients with solid tumors. J. Clin. Oncol.27(15S), (2009) (Abstract e13510).
   Google Scholar
• Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized Phase II study of two different schedules. J. Clin. Oncol.27(25), 4188–4196 (2009).
   PubMed Web of Science ®Google Scholar
• Muss HB, Bundy B, DiSaia PJ et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a Phase III trial of the Gynecologic Oncology Group). Cancer55(8), 1648–1653 (1985).
   PubMed Web of Science ®Google Scholar
• Currie J, Blessing JA, Muss HB, Fowler J, Berman M, Burke TW. Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol. Oncol.61(1), 27–30 (1996).
   PubMed Web of Science ®Google Scholar
• Edmonson JH, Blessing JA, Cosin JA, Miller DS, Cohn DE, Rotmensch J. Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol. Oncol.85(3), 507–510 (2002).
   Google Scholar
• Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol.62(2), 226–229 (1996).
   PubMed Web of Science ®Google Scholar
• Maurel J, Lopez-Pousa A, de Las Penas R et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized Phase II study of the Spanish group for research on sarcomas. J. Clin. Oncol.27(11), 1893–1898 (2009).
   PubMed Web of Science ®Google Scholar
• Patel SR, Gandhi V, Jenkins J et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J. Clin. Oncol.19(15), 3483–3489 (2001).
   PubMed Web of Science ®Google Scholar
• Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2´,2´-difluorodeoxycytidine 5´-triphosphate accumulation by mononuclear cells during a Phase I trial of gemcitabine. Cancer Chemother. Pharmacol.27(4), 258–262 (1991).
   PubMed Web of Science ®Google Scholar
• Bay JO, Ray-Coquard I, Fayette J et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int. J. Cancer119(3), 706–711 (2006).
   PubMed Web of Science ®Google Scholar
• Maki RG, Wathen JK, Patel SR et al. Randomized Phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J. Clin. Oncol.25(19), 2755–2763 (2007).
   PubMed Web of Science ®Google Scholar
• Leitao MM, Brennan MF, Hensley M et al. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol. Oncol.87(3), 287–294 (2002).
   PubMed Web of Science ®Google Scholar
• Weiser MR, Downey RJ, Leung DH, Brennan MF. Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J. Am. Coll. Surg.191(2), 184–190 (2000).
   PubMed Web of Science ®Google Scholar
• Nguyen CL, Scott WJ, Goldberg M. Radiofrequency ablation of lung malignancies. Ann. Thorac. Surg.82(1), 365–371 (2006).
   PubMed Web of Science ®Google Scholar
• Herrera LJ, Fernando HC, Perry Y et al. Radiofrequency ablation of pulmonary malignant tumors in nonsurgical candidates. J. Thorac. Cardiovasc. Surg.125(4), 929–937 (2003).
   PubMed Web of Science ®Google Scholar
• Nakamura T, Matsumine A, Yamakado K et al. Lung radiofrequency ablation in patients with pulmonary metastases from musculoskeletal sarcomas. Cancer115(16), 3774–3781 (2009).
   PubMed Web of Science ®Google Scholar
• O’Cearbhaill R, Maki R, Zheng J et al. Evaluation of the role of thermal ablation in the treatment of soft tissue sarcomas. In: Connective Tissue Oncology Society Annual Meeting. Miami Beach, FL, USA (2009).
   Google Scholar
• Spanos WJ Jr, Perez CA, Marcus S et al. Effect of rest interval on tumor and normal tissue response – a report of Phase III study of accelerated split course palliative radiation for advanced pelvic malignancies (RTOG-8502). Int. J. Radiat. Oncol. Biol. Phys.25(3), 399–403 (1993).
   Google Scholar
• Spanos WJ Jr, Wasserman T, Meoz R, Sala J, Kong J, Stetz J. Palliation of advanced pelvic malignant disease with large fraction pelvic radiation and misonidazole: final report of RTOG Phase I/II study. Int. J. Radiat. Oncol. Biol. Phys.13(10), 1479–1482 (1987).
   PubMed Web of Science ®Google Scholar
• Akhan SE, Yavuz E, Tecer A et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol. Oncol.99(1), 36–42 (2005).
   PubMed Web of Science ®Google Scholar
• Rao UN, Finkelstein SD, Jones MW. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas. Mod. Pathol.12(11), 1001–1009 (1999).
   PubMed Web of Science ®Google Scholar
• Soper JT, McCarty KS Jr, Hinshaw W, Creasman WT, McCarty KS Sr, Clarke-Pearson DL. Cytoplasmic estrogen and progesterone receptor content of uterine sarcomas. Am. J. Obstet. Gynecol.150(4), 342–348 (1984).
   Google Scholar
• Zhai YL, Kobayashi Y, Mori A et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int. J. Gynecol. Pathol.18(1), 20–28 (1999).
   PubMed Web of Science ®Google Scholar
• Uchida T, Nakakawaji K, Sakamoto J et al. The effectiveness of medroxyprogesterone in the treatment of multiple metastasizing leiomyosarcomas: report of a case. Surg. Today26(2), 138–141 (1996).
   PubMed Web of Science ®Google Scholar
• Wade K, Quinn MA, Hammond I, Williams K, Cauchi M. Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol. Oncol.39(3), 364–367 (1990).
   Google Scholar
• Lavie O, Barnett-Griness O, Narod SA, Rennert G. The risk of developing uterine sarcoma after tamoxifen use. Int. J. Gynecol. Cancer18(2), 352–356 (2008).
   PubMed Web of Science ®Google Scholar
• O’Cearbhaill R, Zhou Q, Iasonos A et al. Evaluation of the role of aromatase inhibitors (AIs) in the treatment of uterine leiomyosarcoma (uLMS). J. Clin. Oncol.27 (15S), (2009).
   Google Scholar
• Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, Eisenberg B. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann. Surg. Oncol.8(3), 260–267 (2001).
   PubMed Web of Science ®Google Scholar
• Graeven U, Andre N, Achilles E, Zornig C, Schmiegel W. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J. Cancer Res. Clin. Oncol.125(10), 577–581 (1999).
   PubMed Web of Science ®Google Scholar
• Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J. Clin. Oncol.23(6), 1295–1311 (2005).
   PubMed Web of Science ®Google Scholar
• D’Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J. Clin. Oncol.23(28), 7135–7142 (2005).
   PubMed Web of Science ®Google Scholar
• Verschraegen CF, Quinn R, Rabinowitz I, Arias-Pulido H, Muller C. Phase I/II study of docetaxel (D), gemcitabine (G), and bevacizumab (B) in patients (pts) with advanced or recurrent soft tissue sarcoma (STS). J. Clin. Oncol. (Meeting Abstracts)26(15 Suppl.), (2008) (Abstract 10534).
   Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a Phase II study from the European organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma group (EORTC study 62043). J. Clin. Oncol.27(19), 3126–3132 (2009).
   PubMed Web of Science ®Google Scholar
• Maki RG, D’Adamo DR, Keohan ML et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J. Clin. Oncol.27(19), 3133–3140 (2009).
   PubMed Web of Science ®Google Scholar
• Vigil CE, Chiappori AA, Williams CA et al. Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas. J. Clin. Oncol.26(15 Suppl.), (2008) (Abstract 10535).
   Google Scholar
• Hensley ML, Sill MW, Scribner DR et al. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group Phase II Study. Gynecol. Oncol.115(3), 460–465 (2009).
   PubMed Web of Science ®Google Scholar
• Fleming G. Gemcitabine/docetaxel – welcome to a new standard. Gynecol. Oncol.109(3), 313–315 (2008).
   Google Scholar
• Soria J, Lazar V, Lassau N et al. Sorafenib (S) and dacarbazine (D) combination in patients (pts) with advanced malignant solid tumors: Phase I study with tumor biopsy genomic analysis and dynamic contrast enhanced ultrasonography (DCE-US). J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 3556).
   Google Scholar
• Dupont J, Rothenberg ML, Spriggs DR et al. Safety and pharmacokinetics of intravenous VEGF Trap in a Phase I clinical trial of patients with advanced solid tumors. J. Clin. Oncol.23(16 Suppl.), (2005) (Abstract 3029).
   PubMed Web of Science ®Google Scholar
• Hernando E, Charytonowicz E, Dudas ME et al. The AKT–mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat. Med.13(6), 748–753 (2007).
   PubMed Web of Science ®Google Scholar
• Hu J, Khanna V, Jones M, Surti U. Genomic alterations in uterine leiomyosarcomas: potential markers for clinical diagnosis and prognosis. Genes Chromosomes Cancer31(2), 117–124 (2001).
   Google Scholar
• Chawla SP, Tolcher AW, Staddon AP et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of Phase II trial. J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 10076).
   Google Scholar
• Jones CL, Holmgren E. An adaptive Simon two-stage design for Phase 2 studies of targeted therapies. Contemp. Clin. Trials28(5), 654–661 (2007).
   PubMed Web of Science ®Google Scholar
• Verweij J. Soft tissue sarcoma trials: one size no longer fits all. J. Clin. Oncol.27(19), 3085–3087 (2009).
   PubMed Web of Science ®Google Scholar
• Ren B, Yu YP, Jing L et al. Gene expression analysis of human soft tissue leiomyosarcomas. Hum. Pathol.34(6), 549–558 (2003).
   PubMedGoogle Scholar
• Rushing RS, Shajahan S, Chendil D et al. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. Gynecol. Oncol.91(1), 9–14 (2003).
   PubMed Web of Science ®Google Scholar
• Kushner DM, Webster KD, Belinson JL, Rybicki LA, Kennedy AW, Markman M. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. Gynecol. Oncol.78(2), 221–227 (2000).
   PubMed Web of Science ®Google Scholar
• Gadducci A, Landoni F, Sartori E et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol. Oncol.62(1), 25–32 (1996).
   PubMed Web of Science ®Google Scholar
• Wu TI, Chang TC, Hsueh S et al. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. Gynecol. Oncol.100(1), 166–172 (2006).
   Google Scholar